All financial results are reported in Canadian dollars, unless otherwise stated.
MONTREAL, Nov. 25, 2022 /CNW Telbec/ - Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its fiscal fourth quarter and fiscal year 2022 financial and operating results for the three-month and full year periods ended August 31, 2022.
Fiscal Fourth Quarter and Fiscal Year 2022 Financial and Operational Highlights
Full Year 2022 Business Highlights
"This past year was a tremendous success, and I am very proud of the team at Cannara for their dedication, hard work and support as we continue to strive towards being one of the premier cannabis cultivators in the country," stated Zohar Krivorot, President & Chief Executive Officer of Cannara. "Our state-of-the-art Valleyfield Facility is producing, as of today, seven of its twenty-four growing zones, each containing 9,600 plants each. We remain confident in fulfilling the remaining grow zones over the coming quarters, and our successful harvests should shed any doubt regarding our ability to achieve all of our expansion milestones and bring more premium-grade cannabis to market," concluded Mr. Krivorot.
Nicholas Sosiak, Chief Financial Officer of Cannara added, "Revenues, profits, and net income have all increased over the past 12 months while simultaneously adding new products for our customer base and none of this would be possible without the hard work of the entire Cannara family. Over the last twelve months, we have achieved a ramp up in production which was necessary to support the recent expansion plans to the other provinces. Given the recent expansion to the BC and the financial commitment required for such expansion, I am very proud to be able to report our sixth consecutive quarter of Adjusted EBITDA and a positive net income for our fiscal year end 2022. Our lenders continue to support us, our customers continue to purchase our products and as we continue our rapid growth, we expect to attract new customers throughout Canada who are constantly looking for new product offerings; this is just the beginning." concluded Mr. Sosiak.
Select Financial Information
Three-month periods ended | Years ended | ||||
Selected Financial Highlights | August 31, | August 31, | August 31, | August 31, | |
Gross revenue1 | $ 11,894,302 | $ 6,270,006 | $ 35,482,601 | $ 16,290,045 | |
Other income | 52,810 | 211,733 | 515,157 | 976,960 | |
11,947,112 | 6,481,739 | 35,997,758 | 17,267,005 | ||
Gross profit, before fair value adjustments | 4,759,816 | 3,440,799 | 14,144,868 | 8,741,484 | |
%2 | 40 % | 53 % | 39 % | 51 % | |
Gross profit | 7,103,374 | 4,526,126 | 17,487,636 | 10,543,099 | |
%3 | 59 % | 70 % | 49 % | 61 % | |
Operating expenses | 3,340,653 | 2,959,432 | 12,546,901 | 10,285,816 | |
Net finance expense | 1,209,277 | 434,851 | 2,635,316 | 1,785,426 | |
Net income (loss) | $ 2,553,444 | $ 1,131,843 | 2,305,419 | $ (1,528,143) | |
%4 | 21 % | 17 % | 6 % | -9 % | |
Adjusted EBITDA5 | $ 2,493,253 | $ 1,364,415 | 5,321,022 | $ 1,503,621 | |
%5 | 21 % | 21 % | 15 % | 9 % | |
Basic earnings (loss) per share | $ 0.01 | $ 0.01 | $ 0.01 | $ (0.01) | |
Diluted earnings (loss) per share | $ 0.01 | $ 0.01 | $ 0.01 | $ (0.01) | |
August 31, 2022 | August 31, 2021 | ||||
Cash | $ 12,114,691 | $ 8,159,305 | |||
Accounts receivable | 8,526,918 | 2,847,725 | |||
Biological assets | 5,712,456 | 1,902,206 | |||
Inventory | 13,266,987 | 5,508,258 | |||
Working capital6 | 29,127,599 | 12,412,935 | |||
Total assets | 125,617,047 | 92,022,613 | |||
Total current liabilities | 11,861,085 | 6,833,798 | |||
Total non-current liabilities | 47,020,201 | 21,073,003 | |||
Net assets | 66,735,761 | 64,115,812 | |||
1 Gross revenue included revenue from sale of goods, net of excise taxes, services revenues and lease revenues. | ||
2 Gross profit before fair value adjustments % is determined as Gross profit before fair value adjustments divided by Total revenues. | ||
3 Gross profit % is determined as Gross profit divided by Total revenues. | ||
4 Net income (loss) % is determined as Net income (loss) divided by Total revenues. | ||
5 Adjusted EBITDA and working capital are non-GAAP financial performance measures with no standard definition under IFRS. | ||
Adjusted EBITDA % a non-GAAP financial ratio and is determined as Adjusted EBITDA divided by total revenues. | ||
6 Working capital is determined as total current assets minus total current liabilities. |
Outstanding Shares
As at the date of this report, the Company had 877,481,321 common shares and 45,635,998 stock options issued and outstanding. For further information, the complete Consolidated Financial Statements and Management's Discussion and Analysis for the years ended August 31, 2022 and 2021, along with additional information about the Company and all of its public filings are available at sedar.com and the Company's investor website, investors.cannara.ca.
About Cannara Biotech Inc.
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Québec and Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 125,000kg of potential annualized cultivation output. Leveraging Québec's low electricity costs, Cannara's facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding "Forward-Looking" Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Last Trade: | US$0.56 |
Daily Volume: | 29,748 |
Market Cap: | US$50.410M |
November 25, 2024 July 23, 2024 April 29, 2024 December 07, 2023 July 27, 2023 |
GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...
CLICK TO LEARN MOREUGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS